Use of Angiotensin Receptor Blockers and the Risk of Cancer

Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice

(2010) Chiyo Doi et al.   BMC CANCER

Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis

(2010) Nicolas Clere et al.   INTERNATIONAL JOURNAL OF CANCER

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials

(2010) Ilke Sipahi et al.   LANCET ONCOLOGY

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

(2010) Sripal Bangalore et al.   LANCET ONCOLOGY

A basic study design for expedited safety signal evaluation based on electronic healthcare data

(2010) Sebastian Schneeweiss   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

The Nordic Countries as a Cohort for Pharmacoepidemiological Research

(2009) Kari Furu et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

(2009) E.R. Koomen et al.   Cancer Epidemiology

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults

(2009) et al.   CIRCULATION

Standards of Medical Care in Diabetes--2010

(2009)   DIABETES CARE

Angiotensin inhibition and malignancies: a review

(2009) T Rosenthal et al.   JOURNAL OF HUMAN HYPERTENSION

Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials

(2009) Craig I Coleman et al.   JOURNAL OF HYPERTENSION

The renin-angiotensin system and malignancy

(2008) E. I. Ager et al.   CARCINOGENESIS